TOP TEN perturbations for 39166_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39166_s_at
Selected probe(set): 207714_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39166_s_at (207714_s_at) across 6431 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):4.1439238Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):3.894659Number of Samples:3 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
heat shock study 3 / untreated THP-1 cell sample
Relative Expression (log2-ratio):3.797986Number of Samples:3 / 3
| Experimental | heat shock study 3 |
| Cultured THP-1 mononuclear cells were treated with heat shock (43°C) for 1 hour followed by a 4 hour recovery period at 37°C. | |
| Control | untreated THP-1 cell sample |
| Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):3.5864344Number of Samples:8 / 12
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | HepaRG |
| Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
heat shock study 1 (LPS) / untreated THP-1 cell sample
Relative Expression (log2-ratio):3.4922228Number of Samples:3 / 3
| Experimental | heat shock study 1 (LPS) |
| Cultured THP-1 mononuclear cells were treated with heat shock (43°C; 1h) and lipopolysaccharide (1ug/ml; 4h). | |
| Control | untreated THP-1 cell sample |
| Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C. |
pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample
Relative Expression (log2-ratio):3.4214725Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (expanded; PPRF) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80–90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 8d) / normal pancreatic islet sample
Relative Expression (log2-ratio):3.3087063Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 8d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 8 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 6d) / normal pancreatic islet sample
Relative Expression (log2-ratio):3.2944508Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 6d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 6 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue
Relative Expression (log2-ratio):3.2761002Number of Samples:20 / 9
| Experimental | atypical teratoid/rhabdoid tumor study 1 |
| Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT). | |
| Control | non-tumor brain tissue |
| Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.2446337Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |